GlaxoSmithKline News and Research

RSS

CEO Cancer Gold Standard: Four organizations receive accreditation

The American Cancer Society’s Mid-South Division, LiDestri Foods, MDU Resources Group, Inc. and WCA Hospital have received CEO Cancer Gold Standard™ accreditation, recognizing the commitment of these organizations to taking concrete actions to reduce the cancer risk of employees and their families through screenings, early detection, and healthy changes in lifestyle.

25 Jan 2010

GSK announces new initiatives for addressing healthcare challenges in the world's poorest countries

Andrew Witty, Chief Executive of GlaxoSmithKline, today announced a series of new initiatives targeted at further transforming the company's approach to diseases that disproportionately affect the world's poorest countries. His announcements build on commitments made in 2009 to work in partnership, expand access to medicines and encourage new research into neglected tropical diseases.

22 Jan 2010

DIA Annual EuroMeeting programme in Monaco

The Drug Information Association (DIA) in Europe will host its 22nd Annual EuroMeeting from 8-10 March 2010 in Monaco. The DIA Annual EuroMeeting features more than 110 hot-topic sessions across 13 themes and attracts more than 3,000 professionals from the biopharmaceutical industry, contract service organisations, regulatory agencies, health ministries and academia, as well as patients and students worldwide.

22 Jan 2010

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

BIO Ventures for Global Health, GlaxoSmithKline (GSK), and Alnylam announced today that the organizations are partnering to engage the global health community in using the powerful resources of the GSK and Alnylam Intellectual Property (IP) Pool.

21 Jan 2010

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

21 Jan 2010

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

The Biotechnology Industry Organization (BIO) applauds the joint efforts of BIO members GlaxoSmithKline and Alnylam Pharmaceuticals to encourage research to accelerate medical therapies for neglected diseases and today’s announcement of the selection of BIO Ventures for Global Health (BVGH) as the administrator of the Intellectual Property (IP) Pool.

21 Jan 2010

GSK to offer scientists access to compounds, lab space to fight malaria

Drugmaker GlaxoSmithKline (GSK)'s Chief Executive Officer Andrew Witty on Tuesday unveiled the company's plans to allow "free access to its library of 13,500 potential malaria treatments and devote the profits from its experimental [RTS,S] vaccine to battling tropical illnesses that beset poor countries," Bloomberg reports (Randall, 1/20).

21 Jan 2010

Health shares rise with speculation regarding Massachusetts election

Health shares rose Tuesday as traders considered the prospect that a Republican victory in the special Senate election in Massachusetts could jeopardize the health reform legislation.

21 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

WHO, CDC issue H1N1 updates

Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.

19 Jan 2010

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.

19 Jan 2010

FDA warns consumers about counterfeit and potentially harmful version of Alli capsules

The U.S. Food and Drug Administration is today warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit).

19 Jan 2010

Babraham Institute research may lead to new means of making purified T cells

Research from the Babraham Institute, reported today in the Journal of Experimental Medicine, provides new insights into how our immune system produces T cells, a type of white blood cell that is an essential part of the body's immune surveillance system for fighting infection. The findings pave the way for a new means of making purified T cells, which gets over one of many hurdles faced in the use of T cells in regenerative medicine and transplantations, and in addition will open up new avenues of research and applications in drug and toxicity testing in industry.

18 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

WHO official rejects claims agency overhyped threat of H1N1

Keiji Fukuda, the special adviser to the WHO director general on pandemic influenza, on Thursday dismissed allegations that the agency exaggerated the threat of the H1N1 (swine flu) pandemic and has been influenced by the pharmaceutical industry, the Washington Post reports.

18 Jan 2010

Media outlets examine U.S. plans for leftover H1N1 vaccine, efforts to keep flu vaccine production on track

After working to ensure the U.S. had access to enough H1N1 (swine flu) vaccine, health officials may now face a new dilemma - a vaccine surplus, the Associated Press reports.

12 Jan 2010

Market for chronic tophaceous gout medications will be led by drug that resolves tophi in less than a year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the U.S. and Europe, a drug that resolves tophi in less than one year would become the patient share leader in the chronic tophaceous gout patient subpopulation and would be used in the vast majority of patients who suffer severe tophaceous gout, according to surveyed U.S. and European rheumatologists.

12 Jan 2010

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.

12 Jan 2010

Amira Pharmaceuticals achieves another development milestone in its FLAP program

Amira Pharmaceuticals, Inc. announced today that it has achieved another development milestone in its FLAP program, which is partnered with GlaxoSmithKline. This milestone is related to the successful development of a solid dose formulation, which is critical for future development and commercialization activities.

8 Jan 2010

Developing countries reassess need for donated H1N1 vaccine

As the number of H1N1 (swine flu) cases in some regions of the world continues to fall, developing countries scheduled to receive donated H1N1 (swine flu) vaccines from the WHO are reassessing just how many vaccines their countries need, the Canadian Press reports.

6 Jan 2010

GlaxoSmithKline News and Research

CEO Cancer Gold Standard: Four organizations receive accreditation

GSK announces new initiatives for addressing healthcare challenges in the world's poorest countries

DIA Annual EuroMeeting programme in Monaco

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

GSK to offer scientists access to compounds, lab space to fight malaria

Health shares rise with speculation regarding Massachusetts election

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

WHO, CDC issue H1N1 updates

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

FDA warns consumers about counterfeit and potentially harmful version of Alli capsules

Babraham Institute research may lead to new means of making purified T cells

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

WHO official rejects claims agency overhyped threat of H1N1

Media outlets examine U.S. plans for leftover H1N1 vaccine, efforts to keep flu vaccine production on track

Market for chronic tophaceous gout medications will be led by drug that resolves tophi in less than a year

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

Amira Pharmaceuticals achieves another development milestone in its FLAP program

Developing countries reassess need for donated H1N1 vaccine

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News